Welcome to our dedicated page for Sarepta Therapeutics, news (Ticker: $SRPT), a resource for investors and traders seeking the latest updates and insights on Sarepta Therapeutics, stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Sarepta Therapeutics,'s stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Sarepta Therapeutics,'s position in the market.
Sarepta Therapeutics, Inc. announced that Dr. Jerry R. Mendell, a gene therapy pioneer, was named to the inaugural TIME100 Health list for his contributions in neuromuscular disease treatment and gene therapy advancements, notably Duchenne muscular dystrophy. Dr. Mendell's lifelong dedication to genetic medicine has significantly impacted global health.
Sarepta Therapeutics reported strong financial results for the first quarter of 2024, with net product revenues totaling $359.5 million, a 55% increase from the prior year. ELEVIDYS gene therapy generated $133.9 million in revenue. The company achieved GAAP earnings of $36.1 million and non-GAAP earnings of $78.2 million. Real-world evidence showed that eteplirsen treatment resulted in significant survival benefits for Duchenne muscular dystrophy patients. The FDA is reviewing an efficacy supplement to expand ELEVIDYS's indication.
Sarepta Therapeutics, Inc. granted equity awards under Nasdaq Listing Rule 5635(c)(4) to 24 new employees in April 2024, comprising options to purchase 0 shares of common stock and 17,090 restricted stock units. The options have an exercise price of $126.66 per share, with vesting schedules spread over four years.
